Figure 1.
Figure 1. Changes in VWF and blood volume during pregnancy, and proposed clinical trial. (A) VWF:RCo level during pregnancy. von Willebrand ristocetin cofactor activity in VWD treated patients (in red), in VWD untreated patients, and in pregnant controls. Adapted from James et al.7 (B) Blood volume during pregnancy. Blood volume (blue line) increases 1.5-fold by the eighth month of pregnancy, compared with baseline. Adapted from Liu and Arany.18 (C) PREVENT PPH in VWD trial schema. This is the schema for Prevent Postpartum Hemorrhage in von Willebrand Disease, or PREVENT PPH in VWD, a prospective, randomized, controlled trial in women with VWD. Adapted from Machin et al.25

Changes in VWF and blood volume during pregnancy, and proposed clinical trial. (A) VWF:RCo level during pregnancy. von Willebrand ristocetin cofactor activity in VWD treated patients (in red), in VWD untreated patients, and in pregnant controls. Adapted from James et al. (B) Blood volume during pregnancy. Blood volume (blue line) increases 1.5-fold by the eighth month of pregnancy, compared with baseline. Adapted from Liu and Arany.18  (C) PREVENT PPH in VWD trial schema. This is the schema for Prevent Postpartum Hemorrhage in von Willebrand Disease, or PREVENT PPH in VWD, a prospective, randomized, controlled trial in women with VWD. Adapted from Machin et al.25 

Close Modal

or Create an Account

Close Modal
Close Modal